Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
Obesity is more than a cosmetic concern. It’s a chronic disease that can be treated with drugs like semaglutide (Wegovy) and ...
Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...
Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.
This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. If you’re starting a weight loss journey, you might have ...
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy claims.
According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...